id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-280198-bhjw6xc5	Olaleye, Omonike A.	Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro	2020-08-14		.txt	text/plain	1814	112	49	title: Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 Spike Protein Interaction In Vitro Here in, we discovered Clioquinol (5-chloro-7-iodo-8-quinolinol (CLQ)), a FDA approved drug and two of its analogues (7-bromo-5-chloro-8-hydroxyquinoline (CLBQ14); and 5, 7-Dichloro-8-hydroxyquinoline (CLCQ)) as potent inhibitors of SARS-CoV-2 infection induced cytopathic effect in vitro. In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. Therefore, targeting 106 the interaction between human ACE2 receptor and the RBD in S protein of SARS-CoV-2 could 107 serve as a promising approach for the development of effective entry inhibitors for potential 108 prevention and/or treatment of COVID-19. Activity of Clioquinol (CLQ) and Analogues against ACE2 Exopeptidase Activity and 725 ACE2 and SARS-CoV-2 Spike (RBD) Protein Interaction	./cache/cord-280198-bhjw6xc5.txt	./txt/cord-280198-bhjw6xc5.txt